See more : Bliss GVS Pharma Limited (BLISSGVS.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Heat Biologics, Inc. (HTBX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Heat Biologics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Adocia SA (ADOC.PA) Income Statement Analysis – Financial Results
- Conifer Holdings, Inc. (CNFRZ) Income Statement Analysis – Financial Results
- China Northern Rare Earth (Group) High-Tech Co.,Ltd (600111.SS) Income Statement Analysis – Financial Results
- Ever Supreme Bio Technology Co., Ltd (6712.TWO) Income Statement Analysis – Financial Results
- Hornby PLC (HRN.L) Income Statement Analysis – Financial Results
Heat Biologics, Inc. (HTBX)
About Heat Biologics, Inc.
Heat Biologics, Inc., an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company's therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which has completed enrollment in a Phase II clinical trial to treat patients with advanced non-small cell lung cancer; and HS-130 that is in Phase I clinical trial for the treatment of advanced solid tumors. Its products also include PTX-35, a novel T-cell co-stimulator agonist antibody targeting DR3/TNFRSF25 that is in Phase I clinical trial; DR3/TNFRSF25 for various immunotherapy approaches; and COVID-19 vaccine, which is in preclinical stage. Heat Biologics, Inc. has a collaboration with Dr. James Shapiro at University of Alberta to manufacture surrogate mouse version of PTX-35. The company was incorporated in 2008 and is headquartered in Morrisville, North Carolina.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.11M | 2.95M | 3.05M | 5.79M | 1.52M | 341.64K | 0.00 | 0.00 | 0.00 | 3.11K | 187.79K |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 2.11M | 2.95M | 3.05M | 5.79M | 1.52M | 341.64K | 0.00 | 0.00 | 0.00 | 3.11K | 187.79K |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% |
| Research & Development | 18.82M | 12.94M | 13.01M | 16.23M | 8.27M | 9.33M | 2.60M | 2.86M | 2.74M | 902.94K | 1.25M |
| General & Administrative | 16.83M | 15.00M | 9.43M | 7.03M | 0.00 | 4.14M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 16.83M | 15.00M | 9.43M | 7.03M | 0.00 | 4.14M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 1.88M | 0.00 | 0.00 | 0.00 | 6.37M | 0.00 | 18.43M | 9.33M | 3.83M | 1.44M | 976.00K |
| Operating Expenses | 37.53M | 27.94M | 22.44M | 23.26M | 14.64M | 13.47M | 21.02M | 12.19M | 6.56M | 2.35M | 2.22M |
| Cost & Expenses | 37.53M | 27.94M | 22.44M | 23.26M | 14.64M | 13.47M | 21.02M | 12.19M | 6.56M | 2.35M | 2.22M |
| Interest Income | 815.32K | 566.72K | 431.82K | 265.75K | 22.17K | 31.14K | 66.00K | 40.57K | 10.07K | 2.00 | 517.00 |
| Interest Expense | 127.74K | 0.00 | 0.00 | 0.00 | 0.00 | 549.40K | 364.00K | 73.35K | 79.12K | 101.09K | 63.17K |
| Depreciation & Amortization | -127.74K | 333.15K | 232.51K | 237.32K | 134.08K | 132.08K | 116.00K | 66.90K | 6.35K | 2.59K | 624.00 |
| EBITDA | -35.55M | -25.72M | -19.74M | -16.48M | -12.52M | -11.89M | -19.82M | -11.65M | -8.63M | -2.32M | -2.04M |
| EBITDA Ratio | -1,682.44% | -872.35% | -647.40% | -284.47% | -823.53% | -3,480.96% | 0.00% | 0.00% | 0.00% | -74,486.40% | -1,086.92% |
| Operating Income | -35.42M | -26.12M | -20.75M | -17.96M | -13.34M | -13.13M | -21.02M | -12.19M | -6.56M | -2.34M | -2.03M |
| Operating Income Ratio | -1,676.40% | -886.18% | -680.39% | -309.99% | -877.85% | -3,842.41% | 0.00% | 0.00% | 0.00% | -75,327.23% | -1,083.57% |
| Total Other Income/Expenses | -127.74K | -257.03K | 406.27K | 383.53K | 123.44K | 152.52K | -100.00K | -56.28K | -45.22K | -108.34K | -64.18K |
| Income Before Tax | -35.55M | -26.38M | -20.34M | -17.58M | -13.22M | -12.97M | -21.12M | -12.24M | -6.61M | -2.45M | -2.10M |
| Income Before Tax Ratio | -1,682.44% | -894.90% | -667.07% | -303.37% | -869.73% | -3,797.77% | 0.00% | 0.00% | 0.00% | -78,810.87% | -1,117.75% |
| Income Tax Expense | -145.97K | -257.03K | 45.18K | -985.49K | -809.54K | 701.92K | 264.00K | 17.07K | 33.90K | -7.26K | -1.01K |
| Net Income | -35.40M | -26.05M | -20.02M | -15.73M | -11.84M | -12.57M | -20.30M | -11.79M | -8.71M | -2.42M | -2.10M |
| Net Income Ratio | -1,675.54% | -883.65% | -656.51% | -271.56% | -779.09% | -3,680.44% | 0.00% | 0.00% | 0.00% | -77,819.94% | -1,120.89% |
| EPS | -1.41 | -1.63 | -4.21 | -6.30 | -21.56 | -49.40 | -174.92 | -126.18 | -160.61 | -90.87 | -79.03 |
| EPS Diluted | -1.41 | -1.63 | -4.21 | -6.30 | -21.56 | -49.40 | -174.92 | -126.18 | -160.61 | -90.87 | -79.03 |
| Weighted Avg Shares Out | 25.14M | 15.98M | 4.75M | 2.50M | 549.33K | 254.55K | 116.02K | 93.43K | 54.24K | 26.63K | 26.63K |
| Weighted Avg Shares Out (Dil) | 25.14M | 15.98M | 4.75M | 2.50M | 549.33K | 254.55K | 116.02K | 93.43K | 54.24K | 26.63K | 26.63K |
Roche improves speed and accuracy of non-small cell lung cancer diagnosis with launch of automated digital pathology algorithm
Genprex Receives USAN Approval of Non-Proprietary Name for Lead Drug Candidate
Genprex CEO to Interview Live on “The Big Biz Show”
3 Reasons Jazz Pharmaceuticals Is A Hot Buy Right Now | The Motley Fool
Merck’s KEYTRUDA® (pembrolizumab) Approved in China for Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Whose Tumors Express PD-L1 (CPS ≥10)
FerGene Appoints Top Biotech Leaders to Executive Team
Source: https://incomestatements.info
Category: Stock Reports